- Home
- NCMI vs ZBIO Comparison
NCMI vs ZBIO Comparison
Compare NCMI & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- ZBIO
- Stock Information
- Founded
- NCMI 2005
- ZBIO 2019
- Country
- NCMI United States
- ZBIO United States
- Employees
- NCMI N/A
- ZBIO N/A
- Industry
- NCMI Advertising
- ZBIO
- Sector
- NCMI Consumer Discretionary
- ZBIO
- Exchange
- NCMI Nasdaq
- ZBIO NYSE
- Market Cap
- NCMI 476.2M
- ZBIO 389.2M
- IPO Year
- NCMI 2007
- ZBIO 2024
- Fundamental
- Price
- NCMI $5.18
- ZBIO $9.19
- Analyst Decision
- NCMI Strong Buy
- ZBIO Strong Buy
- Analyst Count
- NCMI 5
- ZBIO 7
- Target Price
- NCMI $7.60
- ZBIO $32.29
- AVG Volume (30 Days)
- NCMI 676.0K
- ZBIO 202.0K
- Earning Date
- NCMI 08-04-2025
- ZBIO 08-16-2025
- Dividend Yield
- NCMI 1.16%
- ZBIO N/A
- EPS Growth
- NCMI N/A
- ZBIO N/A
- EPS
- NCMI N/A
- ZBIO N/A
- Revenue
- NCMI $238,300,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- NCMI $10.10
- ZBIO $206.00
- Revenue Next Year
- NCMI $11.66
- ZBIO $41.92
- P/E Ratio
- NCMI N/A
- ZBIO N/A
- Revenue Growth
- NCMI 42.10
- ZBIO N/A
- 52 Week Low
- NCMI $4.12
- ZBIO $5.83
- 52 Week High
- NCMI $7.60
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- NCMI 46.50
- ZBIO N/A
- Support Level
- NCMI $5.15
- ZBIO N/A
- Resistance Level
- NCMI $5.35
- ZBIO N/A
- Average True Range (ATR)
- NCMI 0.21
- ZBIO 0.00
- MACD
- NCMI 0.02
- ZBIO 0.00
- Stochastic Oscillator
- NCMI 36.84
- ZBIO 0.00
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.